Murex (Canada) launches deoxyribonucleic (DNA)-based cytomegalovirus (CMV) test:
This article was originally published in Clinica
Executive Summary
Murex (Canada) has launched its DNA-based hybrid capture test for cytomegalovirus in Europe. The kit, which gives a quantitative, same-day result, was developed in collaboration with Digene Diagnostics. Murex hopes the availability of a quantitative test will open up a market for treatment monitoring in immunocompromised patients. The kit will be sold only for research use in France, Italy, Spain and the UK, but Murex hopes to launch it for diagnostic use in June. A 510(k) submission in the US is not expected before 1996.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.